The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis
Although the large majority of tuberculosis cases worldwide are drug susceptible, multidrug-resistant tuberculosis (MDR TB) presents an emerging threat to global tuberculosis control. Strains of MDR TB are, by definition, those resistant to the two most potent antituberculosis medications, isoniazid and rifampin. The loss of susceptibility to isoniazid and rifampin makes such strains of tuberculosis more difficult to treat.
This guide is intended to be a resource for physicians and other health care professionals who provide care and treatment to patients with multidrug-resistant tuberculosis (MDR TB) in DOTS-Plus projects. Every effort possible has been made to ensure that the material presented here is accurate, reliable, and in accord with current standards. However, as new research and experience expanding knowledge, recommendations for care and treatment change. It is, therefore, the responsibility of the individual physician or other health care professional to use his/her best medical judgment in determining appropriate patient care or treatment.